SAB Biotherapeutics, Inc.
sab.bioWhat Do They Do?
Develops human antibody treatments for people with immune and autoimmune disorders, including autoimmune diabetes.
10-K for FY2025, filed Mar 9, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$22.5MView ↗
- ▲ +122% (Loss)
- vs −$10.1M in Q2 FY2025
A narrower disease focus
The earlier report described development across autoimmune and infectious, gastroenterological and respiratory diseases, plus oncology; the latest centers its stated focus on immune and autoimmune disorders.
10-K for FY2022, filed Apr 14, 2023 10-K for FY2025, filed Mar 9, 2026We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to…View ↗
Who Do They Compete With?
Competes with Sanofi, Sana Biotechnology, Imcyse, vTv Therapeutics, Century Therapeutics, IM Therapeutics, Sernova, and Biomea Fusion
10-K for FY2025, filed Mar 9, 2026The biopharmaceutical industry is highly competitive and subject to rapid and significant technological change as research provides a…View ↗
Loading...
